Page 537 - IJB-10-4

International Journal of Bioprinting 3D printed substrate for adhesion tests

References replacement in hospitalized cancer pain patients. J Pain Res.
2016;9:993-999.
1. Cilurzo F, Gennari CG, Minghetti P. Adhesive properties: doi: 10.2147/JPR.S116091
a critical issue in transdermal patch development. Expert 12. Minghetti P, Casiraghi A, Cilurzo F, Montanari L.
Opin Drug Deliv. 2012;9(1):33-45. Development of local patches containing melilot extract and
doi: 10.1517/17425247.2012.637107
ex vivo–in vivo evaluation of skin permeation. Eur J Pharm
2. Trenor S, Suggs A, Love B. Influence of penetration Sci. 2000;10(2):111-117.
enhancers on the thermomechanical properties and peel doi: 10.1016/S0928-0987(99)00094-9
strength of a poly (isobutylene) pressure sensitive adhesive. 13. Steven-Fountain A, Atkins A, Jeronimidis G, Vincent J,
J Mater Sci Lett. 2002;21(17):1321-1323. Farrar D, Chivers R. The effect of flexible substrates on
doi: 10.1023/A:1019748112291
pressure-sensitive adhesive performance. Int J Adhes Adhes.
3. Taghizadeh SM, Lahootifard F. Transdermal excipients 2002;22(6):423-430.
effect on adhesion strength of a pressure sensitive adhesive. doi: 10.1016/S0143-7496(02)00018-0
Iranian Poly J. 2003;12(3):243-248.
14. 3M; 2023.
4. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse https://www.3m.com/3M/en_US/bonding-and-assembly-
LF. Transdermal drug delivery system (TDDS) adhesion as us/resources/science-of-adhesion/categorizing-surface-
a critical safety, efficacy and quality attribute. Eur J Pharm energy/
Biopharm. 2006;64(1):1-8.
doi: 10.1016/j.ejpb.2006.03.009 15. Charkoudian JC. A model skin surface for testing adhesion
to skin. J Soc Cosm Chemists. 1988;39:225-234.
5. Minghetti P, Cilurzo F, Casiraghi A. Measuring adhesive
performance in transdermal delivery systems. Am J Drug 16. Kowalski A, Czech Z, Byczyński Ł. How does the surface
Deliv. 2004;2(3):193-206. free energy influence the tack of acrylic pressure-sensitive
doi: 10.2165/00137696-200402030-00004 adhesives (PSAs)? J Coat Technol Res. 2013;10(6):
879-885.
6. Guidance D. Transdermal and Topical Delivery Systems- doi: 10.1007/s11998-013-9522-2
Product Development and Quality Considerations. Food and
Drug Administration; 2019:1-25. 17. Lin S-Y, Lee C-J, Lin Y-Y. Drug-polymer interaction
affecting the mechanical properties, adhesion strength
7. Boehringer-Ingelheim. Catapres-TTS Transdermal and release kinetics of piroxicam-loaded Eudragit E films
Therapeutic System Programmed delivery in vivo of 0.1, 0.2, plasticized with different plasticizers. J Control Release. 1995;
or 0.3 mg Clonidine Per Day, for One Week. Boehringer- 33(3):375-381.
Ingelheim; Updated August 2016. Accessed October 1, 2023. doi: 10.1016/0168-3659(94)00109-8
https://docs.boehringer-ingelheim.com/Prescribing%20
Information/PIs/Catapres%20TTS/CatapresTTS.pdf 18. Gullick DR, Pugh WJ, Ingram MJ, Cox PA, Moss GP.
Formulation and characterization of a captopril ethyl ester
8. Elshoff J-P, Bauer L, Goldammer N, Oortgiesen M, Pesch drug-in-adhesive-type patch for percutaneous absorption.
H, Timmermann L. Randomized, double-blind, crossover Drug Dev Ind Pharm. 2010;36(8):926-932.
study of the adhesiveness of two formulations of rotigotine doi: 10.3109/03639040903585135
transdermal patch in patients with Parkinson’s disease. Curr
Med Res Opin. 2018;34(7):1293-1299. 19. Cilurzo F, Minghetti P, Gennari CG, Casiraghi A, Montanari
doi: 10.1080/03007995.2018.1430559 L. A novel polymethylmethacrylate hydrophilic adhesive
®
9. USFDA. Neupro (Rotigotine Transdermal System) matrix intended for transdermal patch formulations. Drug
Deliv. 2010;17(3):171-177.
Continuous Delivery For Once-Daily Application. US Food doi: 10.3109/10717541003667772
& Drug Administration; Updated June 2006. Accessed
October 1; 2023. 20. Sheu M-T, Chen L-C, Ho H-O. Simultaneous optimization
https://www.accessdata.fda.gov/drugsatfda_docs/label/ of percutaneous delivery and adhesion for ketoprofen
2007/021829lbl.pdf poultice. Int J Pharm. 2002;233(1-2):257-262.
doi: 10.1016/S0378-5173(01)00919-X
10. Novartis. EXELON PATCH Safely and Effectively. Novartis
Pharmaceutical Corporation; Updated December 2018. 21. Schurad B, Tack J, Lipp R. Evaluation of the transdermal
Accessed October 1, 2023. permeation behavior of Proterguride from drug in adhesive
https://www.novartis.com/us-en/sites/novartis_us/files/ matrix patches through hairless mouse skin. Drug Dev Ind
exelonpatch.pdf Pharm. 2005;31(6):505-513.
doi: 10.1080/03639040500215842
11. Arnet I, Schacher S, Balmer E, Koeberle D, Hersberger KE.
Poor adhesion of fentanyl transdermal patches may mimic 22. Taghizadeh SM, Soroushnia A, Mohamadnia F. Preparation
end-of-dosage failure after 48 hours and prompt early patch and in vitro evaluation of a new fentanyl patch based on

Volume 10 Issue 4 (2024) 529 doi: 10.36922/ijb.3735